Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Rigel Pharmaceuticals excels in sales, faces awareness challenges ahead

Rigel Pharmaceuticals demonstrated strong sales performance and efficient cost management in Q4 2022.
The company faces challenges in raising awareness, maintaining persistency, and reaching profitability.
Exploring market opportunities, partnerships, and collaborations position Rigel for future growth.
Competitive trial results and a focus on persistency drive Rigel's competitive edge in the market.

Rigel Pharmaceuticals excels in Q1 with REZLIDHIA and TAVALISSE, faces prescribing behavior challenges

Rigel Pharmaceuticals showcased strong Q1 performance, particularly with REZLIDHIA and TAVALISSE, while facing challenges in understanding prescribing behavior.
The company's focus on differentiated positioning, academic-community growth, and strategic partnerships presents promising opportunities for future expansion.
Financial stability, positive clinician feedback, and ongoing pipeline advancements position Rigel well for continued growth and success in the market.

Rigel Pharmaceuticals reports robust Q2 sales and strategic growth focus

Rigel Pharmaceuticals showcased strong sales performance and product efficacy in Q2, positioning for future growth.
Challenges in managing expenses and strategic decision-making require careful navigation for sustained profitability.
Exploration of new opportunities and continued focus on innovation present avenues for revenue growth and market expansion.
Financial stability, ongoing development programs, and positive market feedback underpin Rigel's strategic direction and growth potential.

Rigel Pharmaceuticals excels in Q3 sales, eyes pipeline expansion

Rigel Pharmaceuticals demonstrated robust sales growth in Q3, managed expenses effectively, and aims for financial breakeven through operational efficiency. The company's strategic focus on pipeline expansion and partnerships positions it well for future growth and innovation.

Rigel Pharmaceuticals posts record sales, eyes growth with Gavreto acquisition

Rigel Pharmaceuticals reported strong financial performance with record sales and net income in Q4 2023.
The acquisition of Gavreto presents growth opportunities in the oncology market.
Challenges include transitioning Gavreto to commercial operations and competition in the targeted therapy space.

Rigel Pharmaceuticals reports strong Q1 performance and growth opportunities

Rigel Pharmaceuticals demonstrated strong performance in Q1 2024 with robust demand for key products and strategic acquisitions.
While facing challenges such as inventory management and financial breakeven, the company is well-positioned for growth.
Opportunities lie in continued sales growth, clinical advancements, and portfolio expansion through in-licensing deals.

Rigel Pharmaceuticals excels in Q2 with strong sales and pipeline progress

Rigel Pharmaceuticals delivered a robust performance in Q2 2024, driven by commercial success, pipeline advancements, and financial discipline. While facing challenges in clinical trial strategies and competitive landscape, the company is well-positioned to capitalize on growth opportunities through product expansions and strategic partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

REZLIDHIA is a potentially market-leading, oral, mutant isocitrate dehydrogenase-1 (mIDH1) inhibitor Phase 2 registrational data supporting the approval showed a 35% CR+CRh rate in mIDH1 R/R AML patients with a median duration of response of 25.9 months Conference call and webcast to be held today at 6:30 p.m. ET SOUTH SAN FRANCISCO, Calif.

Rigel Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Early clinical data support olutasidenib's potential as a treatment for AML and MDS, in both the relapsed/refractory and newly diagnosed settings Olutasidenib showed durable remission in treatment-naïve and relapsed/refractory AML patients, with or without azacitidine PDUFA target action date is February 15, 2023 SOUTH SAN FRANCISCO, Calif. , Nov. 10, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the publication of data in The Lancet Haematology, which summarizes the Phase 1 results of the Phase 1/2 study of olutasidenib, an investigational, oral, small molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1).

Rigel Announces Publication of Early Clinical Data of Olutasidenib in The Lancet Haematology

Rigel (RIGL) delivered earnings and revenue surprises of 15.38% and 1.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Lags Revenue Estimates

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 AM ET Company Participants Dolly Vance - Senior Advisor, Legal & Corporate Affairs Raul Rodriguez - President and CEO Wolfgang Dummer - Executive Vice President and Chief Medical Officer Dave Santos - Executive Vice President and Chief Commercial Officer Dean Schorno - Executive Vice President and Chief Financial Officer Conference Call Participants Carly Kenselaar - Citi Kristen Kluska - Cantor Fitzgerald Eun Yang - Jefferies Dennis Resnick - BMO Capital Markets Operator Greetings, and welcome to the Rigel Pharmaceuticals Financial Conference Call for the Third Quarter 2022. At this time, all participants are in a listen-only-mode.

Rigel Pharmaceuticals, Inc. (RIGL) Q3 2022 Earnings Call Transcript

FDA review ongoing for olutasidenib NDA; preparations underway for potential launch Third quarter TAVALISSE® net product sales of $19.2 million and total revenues of $22.4 million Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif.

Rigel Reports Third Quarter 2022 Financial Results and Provides Business Update

Updated interim analysis from Phase 2 registrational study highlights 35% of mIDH1 R/R AML patients who received olutasidenib achieved CR+CRh with a median duration of 25.9 months Presentations across the Company's commercial and clinical-stage hematology-oncology portfolio underscore commitment in this space SOUTH SAN FRANCISCO, Calif. , Nov. 3, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the upcoming presentation of five posters highlighting data from the Company's commercial and clinical-stage hematology-oncology portfolio at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 10-13, 2022, in New Orleans, LA, and virtually.

Rigel Announces Five Poster Presentations at the Upcoming 64th American Society of Hematology Annual Meeting and Exposition

SOUTH SAN FRANCISCO, Calif. , Nov. 1, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced top-line efficacy and safety results from the FOCUS Phase 3 clinical trial of fostamatinib in hospitalized COVID-19 patients without respiratory failure who have certain high-risk prognostic factors.

Rigel Announces Top-line Results from FOCUS Phase 3 Clinical Trial of Fostamatinib in High Risk Hospitalized COVID-19 Patients

RIGL hoped to expand the label of its drug Tavalisse (fostamatinib), but the failure of the drug in phase 3 appeared to scupper its chances. RIGL sought guidance to see if a reanalysis of the failed phase 3 study might be well received, but it doesn't appear it was.

Rigel Pharmaceuticals Provides An Opportunity For Investors Or An Acquirer

SOUTH SAN FRANCISCO, Calif. , Oct. 27, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2022 financial results after market close on Thursday, November 3, 2022.

Rigel Announces Conference Call and Webcast to Report Third Quarter 2022 Financial Results and Business Update

Rigel (RIGL) decides to back out from the label expansion of fostamatinib for the treatment of patients with warm autoimmune hemolytic anemia (wAIHA) following the FDA???s review.

Rigel (RIGL) to Not Pursue the WAIHA Program, Cut Jobs

--Announces Workforce Reduction-- SOUTH SAN FRANCISCO, Calif. , Oct. 10, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has received guidance from the U.S. Food and Drug Administration (FDA)'s review of the Company's re-analysis of data from the FORWARD Phase 3 trial of fostamatinib for the treatment of patients with warm autoimmune hemolytic anemia (wAIHA).

Rigel Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback

SOUTH SAN FRANCISCO, Calif. , Sept. 6, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, will present at the H.C.

Rigel to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Dolly Vance - Executive Vice President, Corporate Affairs and General Counsel Raul Rodriguez - President and Chief Executive Officer Dave Santos - Executive Vice President and Chief Commercial Officer Wolfgang Dummer - Executive Vice President and Chief Medical Officer Dean Schorno - Executive Vice President and Chief Financial Officer Jorge Cortes - Director, Georgia Cancer Center. Augusta University Conference Call Participants Eun Yang - Jefferies Joe Pantginis - H.C.

Rigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q2 2022 Results - Earnings Call Transcript

Second quarter TAVALISSE® net product sales of $18.6 million and total revenues of $29.8 million Expanded Rigel's hematology-oncology portfolio by entering into an exclusive license agreement with Forma Therapeutics, Inc. for olutasidenib with an expected launch in 2023 Enrollment completed in Rigel's pivotal Phase 3 clinical trial in high-risk patients hospitalized with COVID-19 with top-line data expected year-end Management to host a conference call and webcast today at 4:30 p.m. Eastern Time and will be joined by Key Opinion Leader and olutasidenib Phase 2 clinical trial investigator, Jorge E.

Rigel Reports Second Quarter 2022 Financial Results and Provides Business Update

Forma Therapeutics Holdings

Registrational Phase 2 data demonstrate olutasidenib's potential as a market-leading, oral, mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor for the treatment of relapsed or refractory acute myeloid leukemia FDA has accepted Forma's NDA for olutasidenib, with a PDUFA target action date of February 15, 2023 Forma to receive an upfront payment of $2.0 million and is eligible to receive an additional $17.5 million upon the achievement of certain near-term regulatory, approval, and first commercial sale milestones, as well as potential future development and commercial milestone payments of $215.5 million and tiered royalties in the low-teens to mid-thirties If approved, olutasidenib would be Rigel's second commercial product in hematology-oncology and highly synergistic with Rigel's existing commercial and medical affairs infrastructure Rigel to host conference call today to discuss transaction details at 4:30 p.m. Eastern Time and will be joined by Key Opinion Leader and olutasidenib Phase 2 trial investigator, Jorge E.

Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia

SOUTH SAN FRANCISCO, Calif. , July 26, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2022 financial results after market close on Tuesday, August 2, 2022.

Rigel Announces Conference Call and Webcast to Report Second Quarter 2022 Financial Results and Business Update

Evoke Pharma

Zomedica

What to know about trading biotech stocks in 2022 The post Biotech Penny Stocks Investing Guide appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Biotech Penny Stocks Investing Guide

Acorda Therapeutics

Kinross Gold

Here are three penny stocks to add to your watchlist right now The post Best Penny Stocks to Watch as the Market Crashes Again appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Watch as the Market Crashes Again

Rigel (RIGL) phase III study evaluating fostamatinib in patients with warm autoimmune hemolytic anemia did not demonstrate statistical significance in the primary efficacy endpoint.

Rigel (RIGL) wAIHA Study Fails to Meet Goals, Stock Tanks

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) shares are trading lower after the company announced data from the FORWARD Phase 3 clinical trial of Fostamatinib did not demonstrate statistical significance in the primary efficacy endpoint. Fostamatinib is currently being evaluated in a Phase 3.

Why Rigel Pharmaceuticals Shares Are Falling Today

Rigel Pharmaceuticals Inc (NASDAQ: RIGL) shares are falling on disappointing data from the FORWARD Phase 3 trial of fostamatinib in patients with warm autoimmune hemolytic anemia (wAIHA).  wAIHA is an autoimmune disorder characterized by the premature destruction of healthy red blood.

Rigel Pharmaceuticals' Fostamatinib Flunks In Late-Stage Rare Blood Disorder Trial

Conference call and webcast to be held today at 8:00 a.m. Eastern Time SOUTH SAN FRANCISCO, Calif.

Rigel Announces Top-line Results from FORWARD Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia

MONTREAL, May 24, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into exclusive license and supply agreements with Rigel Pharmaceuticals granting Knight the rights to commercialize fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in Latin America.

Knight Therapeutics Enters into Exclusive License and Supply Agreements with Rigel Pharmaceuticals to Commercialize Fostamatinib in Latin America

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Dolly Vance - EVP, Corporate Affairs and General Counsel Raul Rodriguez - President and Chief Executive Officer Wolfgang Dummer - EVP and Chief Medical Officer Dave Santos - EVP and Chief Commercial Officer Dean Schorno - EVP and Chief Financial Officer Caroline Piatek - Associate Professor of Clinical Medicine Conference Call Participants Eun Yang - Jefferies Gary Nachman - BMO Capital Markets Kalpit Patel - B. Riley Securities Joseph Pantginis - H.C.

Rigel Pharmaceuticals, Inc.'s (RIGL) CEO Raul Rodriguez on Q1 2022 Results - Earnings Call Transcript

Rigel (RIGL) delivered earnings and revenue surprises of -33.33% and 9.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Rigel Pharmaceuticals Stock (RIGL)